Şunu aradınız:: proprietary medicinal product (İngilizce - Slovence)

proprietary medicinal product:
lastniško zdravilo :

non-proprietary medicinal product
generično zdravilo

medicinal product
zdravilo

medicinal product nolo
zdravilo nima veādov

ganfort medicinal product
zdravilo ganfort

committee for proprietary medicinal products
odbor za zdravila za uporabo v humani medicini

medicinal products
zdravila

medicinal products:
farmacevtski izdelki:

bradycardic medicinal products
zdravila, ki povzročajo bradikardijo

medicinal products – interactions
interakcije z zdravili

medicinal products medicinal products
committee for medicini

proprietary medicinal product: any ready-prepared medicinal product placed on the market under a special name and in a special pack.
lastniško zdravilo: vsako zdravilo, pripravljeno za uporabo, ki se daje v promet pod posebnim imenom in v posebni ovojnini.

committee for proprietary medicinal products (second council directive 75/319/eec).
odbor za lastniška zdravila (druga direktiva sveta 75/319/egs).

committee for proprietary medicinal products (chmp) opinion following an article 6(12) referral
odbor za zdravila za uporabo v humani medicini (chmp) mnenje v zvezi z napotitvijo iz Člena 6( 12)

the membership of the committee for proprietary medicinal products and the committee for veterinary medicinal products shall be made public.
Članstvo v odboru za lastniška zdravila ali odboru za zdravila za uporabo v veterini je javno.

the report of the inspectors shall be made available to the commission, the member states and the committee for proprietary medicinal products.
poročilo inšpektorjev se da na vpogled komisiji, državam članicam in odboru za lastniška zdravila.

the agency should be responsible for the adequate coordination between the committee on orphan medicinal products and the committee on proprietary medicinal products;
agencija naj bi bila odgovorna za ustrezno usklajevanje med odborom za zdravila sirote in odborom za lastniška zdravila;

a revision of the "transparency directive" setting minimum rules for pricing and reimbursement procedures for proprietary medicinal products was also announced.
napovedana je bila tudi revizija direktive o preglednosti, ki določa minimalna pravila za oblikovanje cen in postopke povračil za originalna zdravila.

for the provision of appropriate technical support for the committee for proprietary medicinal products and the committee for veterinary medicinal products, and their working parties and expert groups,
zagotavljanje ustrezne tehnične podpore odboru za lastniška zdravila in odboru za zdravila za uporabo v veterini ter njunim delovnim in strokovnim skupinam,

committee for proprietary medicinal products for human use (chmp) opinion following an article 31 referral for agreal and associated names (see annex i)
odbor za zdravila za uporabo v humani medicini (chmp) mnenje v zvezi z napotitvijo v skladu s Členom 31 za agreal in z njim povezana imena (glejte dodatek i)